This invention provides a compound of the formula (I): wherein A and B
are independently CR.sup.12 or N; D and E are each independently CR.sup.9
or N; R.sup.1 represents (C.sub.1-C.sub.6)alkyl; R.sup.2 represents
hydrogen, halogen, hydroxy, (C.sub.1-C.sub.6)alkyl,
halo(C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxy or
(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl; R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.10 and R.sup.11 each independently represent
hydrogen, halogen, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxy, hydroxy(C.sub.1-C.sub.6)alkyl or
(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl; or R.sup.3 and R.sup.4
are taken together with the carbon atom to which they are attached to
form a 3- to 7-membered carbocyclic ring or heterocyclic ring in which
one or two non-adjacent carbon atoms are optionally replaced by an oxygen
atom, a sulfur atom or NH; R.sup.7 and R.sup.9 each independently
represent hydrogen, halogen, (C.sub.1-C.sub.6)alkyl,
halo(C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxy, hydroxy(C.sub.1-C.sub.6)alkoxy,
(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkoxy,
(C.sub.1-C.sub.6)alkylthio, (C.sub.1-C.sub.6)alkylsulfinyl,
(C.sub.1-C.sub.6)alkylsulfonyl, NH.sub.2, [(C.sub.1-C.sub.6)alkyl]NH--,
[(C.sub.1-C.sub.6)alkyl].sub.2N--, H.sub.2N--(C.sub.1-C.sub.6)alkoxy,
(C.sub.1-C.sub.6)alkyl-NH--(C.sub.1-C.sub.6)alkoxy,
[(C.sub.1-C.sub.6)alkyl].sub.2N(C.sub.1-C.sub.6)alkoxy;
H.sub.2N--(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl,
(C.sub.1C.sub.6)alkyl-NH--(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl,
[(C.sub.1-C.sub.6)alkyl].sub.2N(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)a-
lkyl or 5- or 6-membered heterocyclic ring containing at least one
nitrogen atom; R.sup.8 represents halogen, (C.sub.1-C.sub.6)alkyl,
halo(C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxy, hydroxy(C.sub.1-C.sub.6)alkoxy,
(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkoxy,
halo(C.sub.1-C.sub.6)alkylsulfonyl, halo(C.sub.1-C.sub.6)alkylsulfinyl,
halo(C.sub.1-C.sub.6)alkoxy, halo(C.sub.1-C.sub.6)alkylthio,
[(C.sub.1-C.sub.6)alkyl]NH-- or [(C.sub.1-C.sub.6)alkyl].sub.2N--; or
R.sup.7 and R.sup.8, when E is CR.sup.9, are taken together with the
carbon atoms to which they are attached form a 5-8 membered carbocyclic
or heterocyclic ring, in which one or two non-adjacent carbon atoms are
optionally replaced by oxygen, sulfur, N or NH groups, wherein the
carbocyclic ring or the heterocyclic ring is unsubstituted or substituted
with one or more substituents each independently selected from the group
consisting of hydroxy, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy
and hydroxy(C.sub.1-C.sub.6)alkyl; and R.sup.12 represents hydrogen,
halogen, (C.sub.1-C.sub.6)alkyl or hydroxy(C.sub.1-C.sub.6)alkyl; or a
pharmaceutically acceptable salt or solvate thereof. These compounds are
useful for the treatment of disease conditions caused by overactivation
of VR1 receptor such of pain, or the like in mammalian. This invention
also provides a pharmaceutical composition comprising the above compound.